271 related articles for article (PubMed ID: 28440004)
21. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection.
Chuansumrit A; Isarangkura P; Angchaisuksiri P; Sriudomporn N; Tanpowpong K; Hathirat P; Jorgensen LN
Haemophilia; 2000 Mar; 6(2):61-5. PubMed ID: 10781189
[TBL] [Abstract][Full Text] [Related]
22. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
[TBL] [Abstract][Full Text] [Related]
23. Real-World Early Treatment with Room Temperature-Stable Recombinant Factor VIIa in Hemophilia A/B and Inhibitors: SMART-7™ Post Hoc Analyses.
Demartis F; Batorova A; Chambost H; Eshghi P; Karimi M; Kavakli K; El Fegoun SB; Cepo K; Vestergaard LS; Benson G
TH Open; 2017 Jul; 1(2):e130-e138. PubMed ID: 31249918
[TBL] [Abstract][Full Text] [Related]
24. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation.
Bysted BV; Scharling B; Møller T; Hansen BL
Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439
[TBL] [Abstract][Full Text] [Related]
25. Activated recombinant human coagulation factor VII therapy for intracranial hemorrhage in patients with hemophilia A or B with inhibitors. Results of the novoseven emergency-use program.
Arkin S; Cooper HA; Hutter JJ; Miller S; Schmidt ML; Seibel NL; Shapiro A; Warrier I
Haemostasis; 1998; 28(2):93-8. PubMed ID: 10087434
[TBL] [Abstract][Full Text] [Related]
26. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with recombinant factor VIIa.
Lusher J; Ingerslev J; Roberts H; Hedner U
Blood Coagul Fibrinolysis; 1998 Mar; 9(2):119-28. PubMed ID: 9622209
[TBL] [Abstract][Full Text] [Related]
28. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
29. [Relevance of a single dose of 270 microg/kg recombinant factor VIIa for the treatment of patients with haemophilia and inhibitors - Recommendations from the GTH experts].
Auerswald G; Muntean W; Kemkes-Matthes B; Klamroth R; Krause M; Kurnik K; Oldenburg J; Pabinger-Fasching I; Schramm W; Zimmermann R; Zotz RB
Hamostaseologie; 2009 May; 29(2):197-203. PubMed ID: 19404511
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.
Croteau SE; Nakar C; Neufeld EJ; Shapiro A; Cooper DL
Pediatr Blood Cancer; 2016 Oct; 63(10):1822-8. PubMed ID: 27232114
[TBL] [Abstract][Full Text] [Related]
31. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic properties of two different recombinant activated factor VII formulations.
Morfini M; Jiménez-Yuste V; Eichler H; Fischer R; Kirchmaier CM; Scharling B; Bjerre J
Haemophilia; 2012 May; 18(3):431-6. PubMed ID: 21999231
[TBL] [Abstract][Full Text] [Related]
33. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).
Young G; Cooper DL; Gut RZ;
Haemophilia; 2012 Nov; 18(6):990-6. PubMed ID: 22631073
[TBL] [Abstract][Full Text] [Related]
34. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
Qi X; Zhao Y; Li K; Fan L; Hua B
Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
[TBL] [Abstract][Full Text] [Related]
35. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors.
Bykov K; Bohn RL; Ewenstein BM; Seeger JD; Avorn J; Bateman BT
Thromb Haemost; 2017 Dec; 117(12):2267-2273. PubMed ID: 29212114
[TBL] [Abstract][Full Text] [Related]
36. Optimizing on-demand treatment with NovoSeven room temperature stable.
Negrier C
Haemophilia; 2010 May; 16 Suppl 3():35-40. PubMed ID: 20586800
[TBL] [Abstract][Full Text] [Related]
37. Clinical experience with activated factor VII: focus on safety aspects.
Roberts HR
Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
[TBL] [Abstract][Full Text] [Related]
38. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
39. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
[TBL] [Abstract][Full Text] [Related]
40. A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A; Fukutake K; Takamatsu J; Shima M; Hanabusa H; Mugishima H; Amano K; Takedani H; Tamashima S; Matsushita T; Tawa A; Tanaka I; Higasa S; Kosaka Y; Fujii T; Sakai M; Migita M; Kawakami K; Ohashi Y; Saito H
Haemophilia; 2013 Nov; 19(6):853-60. PubMed ID: 23738888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
